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Supplemental Materials and Methods 
Cells and cell culture 
Madin-Darby canine kidney (MDCK; ATCC) and human embryonic kidney (HEK) 293T (ATCC) 
cells were grown in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 
10% Fetal Bovine Serum (FBS; labtech.com), 1% penicillin-streptomycin (Invitrogen) and 1% 
non-essential amino acids (Gibco). Cell lines were maintained at 37 °C and 5% CO2.  
Virus and Drugs 
The A(H1N1)pdm09 virus A/England/195/2009 (Eng195) was grown from a reverse genetic 
rescued virus as described previously (1). Favipiravir was kindly provided under an MTA by 
Toyama Chemical Co., dissolved in DMSO and stored in aliquots at -20 °C. F-RTP was 
synthesized by Santa-Cruz Biotechnology, dissolved in water and stored in aliquots at -20 °C. 
Virus inhibition assay 
Virus was added at an MOI of 0.002 to 6-well plates of confluent MDCKs and allowed to 
adhere. After an hour, the supernatant was removed and replaced with FBS-free media with 
1 µg/ml of trypsin (Worthington) and either drug or an equivalent volume of a DMSO 
control. Virus infected cells were incubated at 37 °C and 5% CO2 for 48 hours. The 
supernatant was then assayed for infectious virus by plaque assay. Virus inhibition was 
calculated as the percentage of plaques in the presence of drug compared to the absence of 
drug.  
Experimental Evolution Protocol 
Populations of Eng195 viruses were grown in 6-well plates of MDCK for 48 hours at an MOI 
of 0.002 in the presence of favipiravir or a DMSO control. After 48 hours, multiple aliquots 
of the supernatant were frozen and stored. Supernatants were titrated by plaque assay 
every second passage and diluted before the next passage to achieve the same MOI. 
Populations were passaged 10 times with 3 µM for passages 1-4 and 3.5 µM for passages 5-
10. 
Sequencing 
Passage 10 populations were sequenced at Public Health England. Viral RNA was amplified 
using a multisegment RT-PCR strategy (2). Amplicons were sequenced using Nextera library 
preparation with an Illumina MiSeq platform. Next generation data was mapped to the 
Eng195 reference (GQ166654-GQ166661) using BWA v.0.7.5 and variants were identified by 
QuasiBAM (3). Subsequently, plaques were picked and amplified in 6-well plates for Sanger 
sequencing. RNA was extracted from the viral supernatant using QiaAMP Viral Mini kit 
(Qiagen). RNA was reverse transcribed using Superscript III (Invitrogen) and random 
primers. Gene specific primers were used for PCR (4). Sanger Sequencing was performed by 
GATC Biotech and sequences analyzed manually using Geneious (v6). 
Minigenome Assay 
In order to measure polymerase activity in cell culture, pCAGGS plasmids containing genes 
encoding PB1, PB2, PA and NP from Eng195 (pCAGGS-PB1, pCAGGS-PB2, pCAGGS-PA and 
pCAGGS-NP, respectively, at 0.08, 0.08, 0.04, 0.12 µg) were transfected into 293T cells using 
Lipofectamine 3000 (Thermo Fisher). As reporter construct, we transfected 0.08 µg PolI-luc, 
which encodes a minigenome containing a firefly reporter flanked by influenza A promoter 
sequences. 0.1 µg pCAGGS-Renilla luciferase was transfected as a transfection and toxicity 
control. After 21 hours, the Dual-Luciferase Reporter Assay kit (Promega) was used to lyse 
cells and measure luciferase activity. Polymerase activity was expressed as the ratio of 
Firefly:Renilla. Additional experiments used pCAGGS plasmids containing genes from H3N2 
(A/Victoria/3/1975) and H7N9 (A/Anhui/1/2013) the latter kindly provided by Prof. Munir 
Iqbal. 
Rescue of recombinant influenza virus by reverse genetics 
The 12-plasmid viral rescue system has been previously described (5). Briefly, 8 PolI 
plasmids encoding the 8 genome segments of A/Eng/195/2009 virus were transfected with 
‘helper’ plasmids pCAGGS-PB1, pCAGGS-PB2, pCAGGS-PA and pCAGGS-NP into HEK 293T 
cells using x-tremeGENE 9 (Sigma-Aldrich). After 16 hours, cells were detached and allowed 
to reattach in a co-culture with MDCK cells. Viruses were harvested after 3 days. PolI 
plasmids containing mutations of interest were generated using site-directed mutagenesis 
(QuikChange Lightning, Agilent).  
Next-Generation Sequencing with Primer ID 
This technique has been previously described elsewhere (3). A minigenome assay was 
performed with both luciferase minigenome reporter and an additional PolI H3 HA plasmid. 
RNA was extracted and reverse transcribed using Superscript III and a barcoded primer 
specific to H3 HA. qPCR was performed to quantify cDNA and ensure that equal numbers of 
barcoded viral RNA for each sample were sequenced. Following PCR, library preparation was 
performed using NebNext Ultra II (NEB). Samples were sequenced on an Illumina MiSeq 
machine and the data analyzed using a pipeline in Python and R as described in Goldhill et 
al. (3). A minimum cut off of 4 reads was imposed for barcode viral RNAs to be included in 
the analysis. The sequence data can be found at https://www.ebi.ac.uk/ena under project 
number PRJEB27963. The code that was used to run these sequence analyses can be found 
at https://github.com/Flu1/Favipiravir. 
In vitro transcription assays 
A synthetic 11-nt long RNA (ppGAAUACUCAAG) was capped with a radiolabeled cap-1 
structure using 0.25 µM [α-32P]GTP (3,000 Ci mmole−1, Perkin-Elmer), 2.5 U/µl 2’-O-
methyltransferase (NEB) and a vaccinia virus capping kit (NEB). The capped RNAs were 
purified using an Oligo Clean and Concentrator kit (Zymo Research) and eluted in 50 μl 
water. Recombinant polymerase preparations were prepared by transfecting 4 µg of 
plasmids pCAGGS-PA, pCAGGS-PB1 and pCAGGS-PB2-TAP into HEK 293T cells in a 10-cm 
dish using Lipofectamine 3000. After 48 hours, the expressed polymerases were extracted 
and purified as described previously (6). Extensions were performed as 4-μl reactions that 
contained: 1 mM DTT, 5 mM MgCl2, 1 U/μl RNAsin (Promega), 1500 cpm capped RNA 
primer, 0.7 μM 3’ vRNA promoter (5’-GGCCUGCUUUCGCU (3’ 4C template), 5’-
GGCCUGCUUUUGCU (3’ 4U template)), 0.7 μM 5’ vRNA promoter (5’-AGUAGAAACAAGGCC), 
5% glycerol, 0.05% NP-40, 75 mM NaCl, 10 mM HEPES pH 7.5, 500 μM UTP, 500 μM CTP, 
500 μM F-RTP, and 2 μl RdRP. The ATP and GTP concentrations were varied as indicated. 
The reactions were incubated for 60 min at 30 °C and stopped with 4 μl formamide loading 
buffer. Samples were subsequently denatured and analyzed by 20% denaturing PAGE. The 
extended capped primers were visualized and quantified by phosphorimaging. P-values 
were determined using ANOVA with multiple testing or a two-sided t-test in Prism 7. 
 
In vitro replication assays 
Replication assays were performed as 4-μl reactions that contained: 1 mM DTT, 5 mM 
MgCl2, 1 U/μl RNAsin (Promega), 500 μM ApG (Jena Bioscience), 0.7 μM 3’ vRNA promoter 
(5’-GGCCUGUUUUUACU (promoter up template)), 0.7 μM 5’ vRNA promoter, 5% glycerol, 
0.05% NP-40, 75 mM NaCl, 10 mM HEPES pH 7.5, 500 μM UTP, 50 μM ATP, 500 μM CTP, 500 
μM F-RTP, 5 μM GTP, 0.1 μM [α -32P]GTP, and 2 μl RdRP. The reactions were incubated for 
60 min at 30 °C, stopped with 4 μl formamide loading buffer, and analyzed by 20% 
denaturing PAGE. The replication signals were quantified by phosphorimaging and P-values 
were determined using ANOVA with multiple testing. 
Structural modelling 
To model an F-RTP base paired with a C in the influenza A virus RdRP structure, we 
superposed the bat influenza A virus RdRP (PDB 4WSB) with the phi6 RdRP P2 initiation 
complex (PDB 1HI0) in Pymol 1.8.7 through structural alignment of motifs A and C. The F-
RTP was manually inserted using the F-RMP coordinates from the hypoxanthine guanine 
phosphoribosyltransferase-F-RTP complex (PDB 4KN6). PB1 K229 was mutated to R using 
conservative backbone-dependent rotamer selection in Pymol 1.8.7.  
 
 
 
 
 
 
 
 
Supplemental Figure 1. Experimental evolution leads to resistance to favipiravir following 
10 passages. A) Virus titers from each passage for control populations (C1-C3) and 
populations exposed to drug (F1-F3). B) Virus inhibition assay with 5 µM favipiravir for 
Eng195, population F2: passage 10 and 4 plaques taken from population F2: passage 10. 
Error bars are ± SD n=3, 1-way ANOVA with Dunnett’s Multiple Comparison Test, *= P<0.05, 
***= P<0.001. 
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Supplemental Figure 2. PB1 K229R prevents transition mutations caused by favipiravir. 
The mutations from Figure 5B were subdivided into transversions and each individual 
transition.  Individual mutations per 10,000 sequenced nucleotides above the control (0 µM, 
Eng195) were measured by primer ID at 0, 10 and 100 µM favipiravir from RNA expressed in 
a minigenome assay with reconstituted polymerases. A) Eng195, B) PB1 K229R, C) PA P653L 
and D) PB1 K229R + PA P653L. Each point is an average of 2 replicates.  
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Supplemental Figure 3. Expression of wild type and mutant polymerases. Silverstain (top) 
and Western blot analysis of purified influenza A virus RNA polymerase complexes.   
 
 
 
 
 
 
  
Supplemental Figure 4 The P653L mutation favours the C product during transcription in 
vitro. A) PAGE analysis of influenza A virus transcription initiation on a 4U 3’ promoter using 
a radiolabeled capped primer. The C-product (CP) and G-product (GP) are indicated. In 
addition, the realignment products (RP) are marked, which are generated when the 
polymerase realigns a partially extended elongation product from 3’ 4U to 1U (6), thereby 
extending CP and GP by 3 nt. B) Quantitation of CP and GP formation normalized by the 
total RNA polymerase activity. Error bars are ± SD, n=3, 1-way ANOVA with Dunnett’s 
Multiple Comparison Test, *=P<0.5, **= P<0.01, ***= P<0.001, ****=P<0.0001, and ns= not 
significant. 
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